Justin Vinh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Justin Vinh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexi A. Wright
Dana-Farber Cancer Institute 1 Boston, MA
2 shared publications - Charlotta Lindvall
Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA
2 shared publications - James Aaron Tulsky
Department of Psychosocial Oncology and Palliative Care Dana‐Farber Cancer Institute Boston Massachusetts USA
2 shared publications - John Yohan Rhee
Division of Adult Palliative Care, Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA
2 shared publications - Paul J. Miller
Division of Adult Palliative Care, Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA
2 shared publications - Alexander Finnemore
Division of Adult Palliative Care, Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publication
Latest Publications
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218279
Characteristics, Diagnosis, and Treatment of Aphasia in Patients With Brain Tumors
Background and ObjectivesTumor-related aphasia (TRA) affects approximately 24% of patients with brain tumors and significantly influences quality of life; yet, few studies have examined TRA across ...
- 11 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218279
Characteristics, Diagnosis, and Treatment of Aphasia in Patients With Brain Tumors
Background and ObjectivesTumor-related aphasia (TRA) affects approximately 24% of patients with brain tumors and significantly influences quality of life; yet, few studies have examined TRA across ...
- 15 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501360
When Is the Right Time? A Qualitative Study of Timing of Specialty Palliative Care in Patients With Brain Tumors
PURPOSE: To understand from patients, care partners (P/CPs), and physicians the ideal timing of specialty palliative care (SPC) involvement. METHODS: Using a framework of phenomenology and care ethics, we analyzed interviews through a thematic analysis approach. Two investigators independently coded transcripts of recorded interviews. P/CPs were recruited from a single hospital clinic from multiple different oncologists. Physicians were recruited via purposeful snowball sampling based on their knowledge and expertise. RESULTS: Thirty-one participants were recruited: 14 (45%) P/CPs and 17 (55%) clinicians. The mean age of P/CP was 49 years, whereas clinicians' mean age was 44 years. Half of P/CPs were female, and a similar portion of clinicians (53%) were female. More than half of patients had gliomas (57%), and all clinicians were physicians who had practiced neuro-oncology for a mean of 12 years. We identified four themes: (1) Participants felt patients would have benefited from earlier SPC, but there were slight differences in timing based on brain tumor type and grade; (2) neuro-oncology patients have unique supportive care needs compared to other cancers; (3) specialty knowledge of neuro-oncology is important to P/CP for advance care planning, prognostication, and anticipatory guidance; and (4) the broadly intensive role played by care partners in neuro-oncology means they have equally heavy supportive needs. CONCLUSION: This is one of the first studies to explore timing of SPC for patients with CNS tumors. P/CPs and clinicians agreed that early, time-based SPC is beneficial for management of high-grade tumors. Increasing knowledge of neuro-oncology among SPC clinicians working with this population is an area for further study.
- 15 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501360
When Is the Right Time? A Qualitative Study of Timing of Specialty Palliative Care in Patients With Brain Tumors
PURPOSE: To understand from patients, care partners (P/CPs), and physicians the ideal timing of specialty palliative care (SPC) involvement. METHODS: Using a framework of phenomenology and care ethics, we analyzed interviews through a thematic analysis approach. Two investigators independently coded transcripts of recorded interviews. P/CPs were recruited from a single hospital clinic from multiple different oncologists. Physicians were recruited via purposeful snowball sampling based on their knowledge and expertise. RESULTS: Thirty-one participants were recruited: 14 (45%) P/CPs and 17 (55%) clinicians. The mean age of P/CP was 49 years, whereas clinicians' mean age was 44 years. Half of P/CPs were female, and a similar portion of clinicians (53%) were female. More than half of patients had gliomas (57%), and all clinicians were physicians who had practiced neuro-oncology for a mean of 12 years. We identified four themes: (1) Participants felt patients would have benefited from earlier SPC, but there were slight differences in timing based on brain tumor type and grade; (2) neuro-oncology patients have unique supportive care needs compared to other cancers; (3) specialty knowledge of neuro-oncology is important to P/CP for advance care planning, prognostication, and anticipatory guidance; and (4) the broadly intensive role played by care partners in neuro-oncology means they have equally heavy supportive needs. CONCLUSION: This is one of the first studies to explore timing of SPC for patients with CNS tumors. P/CPs and clinicians agreed that early, time-based SPC is beneficial for management of high-grade tumors. Increasing knowledge of neuro-oncology among SPC clinicians working with this population is an area for further study.